Ipamorelin

No — it's not an FDA-approved drug and isn't sold at retail pharmacies. There is no approved label for it to be prescribed off; licensed clinicians prescribe it and compounding pharmacies prepare it. It also has no lawful compounding route: the FDA placed ipamorelin in its Category 2 "significant safety risk" list in 2023, and in 2024 its 503A nomination was withdrawn and the Pharmacy Compounding Advisory Committee reviewed it. It now sits in no 503A category, has not been added to the 503A bulks list and was not on the July 2026 PCAC agenda, and for outsourcing facilities (503B) it is still in Category 2. Confirm current availability with your provider.

Not to compound, even with a prescription. Section 503A lets a pharmacy compound only from an ingredient of an FDA-approved drug, a substance with a USP monograph or one on the FDA's 503A bulks list, and the FDA's interim policy adds its category 1 while it decides. Ipamorelin is in none of these: its 503A nomination was withdrawn in 2024, and an advisory committee reviewed it that October without the FDA adding it to the list. For outsourcing facilities (503B) it sits in category 2, the FDA's list of substances with significant safety risks. Some telehealth providers prescribe it anyway and have a 503A pharmacy prepare it. Buying it from "research chemical" sellers without a prescription is not a lawful supply route for human use, and the quality of those products is untested. We only feature providers and pharmacies with verifiable licensing. Availability can vary by state — confirm current access with the provider or your clinician.

In the small human studies published so far, reported side effects were typically mild: injection-site irritation, occasional headache, transient water retention. The FDA has flagged serious adverse events in one study involving IV administration for gastric motility, and there are spontaneous reports of chronic kidney disease in FAERS (passive reporting, causality unclear). Discuss your full medical history with your provider before starting.

The honest answer is that human data is too thin to have produced an interaction profile — two published studies, one of them a trial that missed its endpoint. One thing is characterized: growth hormone works against insulin, and what repeated GH pulses do to glucose regulation over months has not been studied, so anyone with diabetes or insulin resistance needs close monitoring. Always disclose your full medication list to your provider.

In the price table on this page, the monthly figure is about $150, read on November 4, 2026. Some sellers price it per vial or unit instead, shown in the same table. Nobody we track prices ipamorelin alone: those figures are for ipamorelin combined with CJC-1295. Like CJC-1295 it went onto the FDA's Category 2 list in 2023 and came off in 2024 pending the advisory process. The dose and the vial size both move the figure, so the only number that means anything is the one your provider puts in writing. Insurance does not cover compounded medications.

They start a growth-hormone pulse through two different receptors: sermorelin copies GHRH, the signal from the hypothalamus, and ipamorelin copies ghrelin. That is why clinics often sell them together. Neither has been tested in a large trial in adults, and no study has compared them. The bigger difference is legal: sermorelin can be compounded with a prescription, and ipamorelin has no route through a 503A pharmacy.

Both raise growth hormone, through different receptors: tesamorelin through the GHRH receptor, ipamorelin through the ghrelin receptor. Tesamorelin is an FDA-approved drug with two Phase 3 trials behind it. Ipamorelin was never approved, and in the one trial that reported results it missed its endpoint. Under current FDA rules neither can be lawfully compounded, for different reasons. No trial has compared the two.